To Get more Insights,  Request A Free Sample 

Key Trend Analysis in the Organ Care Products Market 

• The Paradigm Shift to Active Perfusion: The market is rapidly moving beyond traditional static cold storage towards active, warm perfusion technologies. This trend is fueled by growing clinical data from studies in 2024 showing that systems like NMP reduce post-transplant complications, making it the emerging standard of care for improving organ viability.
• Integration of Data-Driven Organ Assessment: Newer organ care devices are evolving from simple preservation containers into sophisticated diagnostic platforms. These systems provide real-time metabolic and functional data, enabling surgeons to make objective, data-backed decisions on organ quality and suitability for transplant, a significant leap from previous subjective assessments.
• Enabling Transplants of More Complex Organs: Technological breakthroughs, such as the 2024 launch of the PancreasPak, are opening up new frontiers. The market is expanding beyond traditional organs to enable more complex and historically challenging procedures, creating new, high-value niches for specialized preservation solutions.
• Decentralization and Competition via Multi-Vendor Contracts: The 2024 decision by U.S. authorities to award multi-vendor contracts for the first time in four decades is a disruptive trend. This move dismantles long-standing monopolies, fostering a more competitive environment that encourages innovation, reduces costs, and accelerates the adoption of cutting-edge organ care technology from a wider range of suppliers.

Measuring Success: The Quantifiable Clinical and Economic ROI of Advanced Organ Preservation Technology

For stakeholders in the organ care products market, the value proposition has shifted from simple preservation to delivering measurable financial and clinical returns. A 2024 analysis reveals that using Normothermic Machine Perfusion (NMP) for livers directly reduces the average hospital stay for recipients by 2.1 days, a significant cost saving for institutions. Similarly, for kidneys, a 2024 study showed that hypothermic machine perfusion cuts delayed graft function incidents by 7 cases per 100 transplants, while another review found perfusion-preserved kidneys required 1 fewer post-operative dialysis session on average. 

The impact on efficiency is profound; advanced cardiac preservation systems added a 3-hour average increase to the viable time window for transplants in 2024, and devices with integrated data monitoring reduced on-site organ assessment time by an average of 45 minutes. This technology is also expanding the organ pool, with a 2024 trial showing advanced lung perfusion enabled the successful transplant of 15 lungs initially deemed unsuitable. For every 50 livers assessed with ex-vivo perfusion in 2024, an average of 4 additional organs were transplanted. The direct economic benefits are compelling: a 2025 analysis calculated that for every 10 DCD heart transplants, 3 patient-years of high-cost treatment are saved, while portable perfusion systems reduced the need for emergency medical flights by 1 in every 8 cross-country transfers in 2024.

Maximizing the Gift of Life: Unlocking the Vast Potential of Expanded Criteria Donors

The most critical challenge facing the transplant community in the organ care products market is organ scarcity, and advanced organ care products are now the primary tool for unlocking the vast potential of the expanded criteria donor (ECD) pool. In 2024, using these technologies enabled a record of nearly 8,200 transplants from donors aged 55 and older in the U.S. The clinical impact is granular and impressive: for kidneys from donors over 60, utilization increased by 6 organs per 100 recovered, and the discard rate for high-KDPI kidneys was reduced by 5 organs for every 50 recovered when machine perfusion was used. This technology is essential for Donation after Circulatory Death (DCD) programs, supporting the growth of DCD heart transplants to over 250 in the U.S. in 2024 and allowing OPOs to recover 3 additional livers for every 20 DCD donors. 

The ability to assess and improve marginal organs is transformative in the organ care products market. For instance, a 2025 study showed NMP reversing warm ischemia damage in 9 out of 15 tested DCD livers, while a 2024 analysis saw 4 out of 10 previously declined fatty livers successfully transplanted after NMP assessment. Furthermore, ex-vivo lung perfusion (EVLP) enabled the transplant of 22 additional lungs from donors with a smoking history in 2024, and perfused hearts from hypertensive donors showed a 12-point functional assessment score improvement. This is all supported by improved logistics, as portable perfusion increased the viable transport distance for ECD organs by 250 miles in 2024.

Segmental Analysis 

Kidney's Reign: Why It Commands the Organ Care Products Market

The kidney segment's unparalleled dominance, capturing over 28% of revenue, is a direct reflection of staggering global health trends and targeted innovation within the organ care products market. Chronic Kidney Disease (CKD) is the primary catalyst, affecting a vast global population—estimated between 9.1% and 13.4%—with over 2 million people annually reaching end-stage renal disease. In the United States alone, 1 in 7 adults, or 37 million people, suffer from CKD, driven largely by high blood pressure and diabetes. This widespread prevalence translates into immense and sustained demand for transplants, evidenced by the U.S. waiting list exceeding 90,000 people as of early 2025. The sheer volume of kidney procedures performed far outpaces that of other organs, creating a high-consumption environment for essential preservation solutions and perfusion systems that are critical for success, thereby cementing the kidney’s financial leadership in this vital healthcare sector.

• Policy Impact: As of January 1, 2023, Medicare Part B began offering lifetime coverage for immunosuppressive drugs, significantly boosting transplant accessibility.
• Future Incentives: The Increasing Organ Transplant Access (IOTA) Model, starting July 1, 2025, will financially reward hospitals for increasing kidney transplant volumes.
• Favorable Reimbursement: North America's market leadership is strongly supported by favorable reimbursement policies that cover the full cost of living donor care.

This position in the organ care products market is further fortified by a wave of technological and policy advancements. Innovations in machine perfusion are pivotal; hypothermic machine perfusion (HMP) is now the standard for preserving higher-risk kidneys, while normothermic machine perfusion (NMP) is gaining ground for assessing and reconditioning organs. This progress is backed by strategic investments, such as the National Kidney Foundation's Innovation Fund supporting ImmunoFree in January 2024 to develop anti-rejection therapies and Northernmost in February 2025 for its portable NoMo™ HMP device. Furthermore, ZeitLife is poised to enter the market with advanced NMP fluids within 2 to 5 years from late 2024. Policy changes by the Organ Procurement and Transplantation Network (OPTN) in 2024 and 2025 have further refined allocation, ensuring these advanced preservation technologies are utilized effectively and solidifying the kidney's profitable and life-saving role.

Wheeled Guardians: Trolleys Dominate In-Hospital Organ Transport Logistics

Trolley-based systems have solidified their status as the most prominent product category, generating an impressive 53% of revenue in the organ care products market through their function as comprehensive, mobile life-support units. Their dominance over smaller, portable products stems from their indispensable role in intra-hospital logistics. Designed as large, wheeled platforms, trolleys integrate complex features like advanced cooling units and oxygenation systems, providing a stable and controlled environment essential for organ viability. This preference is mirrored in broader medical purchasing trends, with cart/trolley systems holding over 50% of the market in the related ultrasound field in 2024. Hospitals are increasingly dedicating capital spending to these advanced trolleys, recognizing their crucial contribution to preserving organs during the critical transfer between the operating room, transport vehicle, and recipient surgical suite, a phase where stability and power are paramount.

• Robust Construction: Most medical trolleys are built from impervious materials like stainless steel, ensuring rapid and effective disinfection for superior hygiene.
• Integrated Technology: The inherent stability of cart designs is crucial for housing high-performance perfusion and imaging components required for modern organ care.
• Customizable Platforms: The modular and flexible design of contemporary hospital transfer carts allows them to be adapted to meet evolving clinical requirements.

The operational advantages of trolleys extend beyond simple transport, fundamentally enhancing hospital workflows and patient outcomes, strengthening its position in the organ care products market. Their maneuverability saves valuable time and reduces manual labor costs, while their organized layout minimizes retrieval time for busy medical staff. Advanced systems, such as the SherpaPak used for heart transport, leverage this platform to provide real-time temperature and location data via Bluetooth to the entire transplant team. Moreover, perfusion systems mounted on these trolleys enable medical teams to analyze an organ's key parameters as if it were a patient in an ICU. This capability can significantly extend the viable preservation time, accommodating more complex or delayed surgeries without compromising the organ's health. The use of these specialized, trolley-integrated transport containers is now considered a vital component for successful organ transplantation.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America: The Uncontested Leader in Transplant Volume and Innovation

North America with over 56% market share, led by the United States, unequivocally commands the leading position in the organ care products market, driven by unparalleled transplant volumes and a robust ecosystem of innovation. The scale of the U.S. market is staggering; in 2024 alone, a record 48,149 organ transplants were performed, averaging 132 procedures each day. This immense procedural volume, supported by 16,988 deceased and 7,030 living donors, resulted in over 45,000 organs being recovered and successfully transplanted. This high-throughput environment creates a massive, sustained demand for advanced preservation and transport solutions. The market’s sophistication is further underscored by significant government investment; the U.S. Senate’s allocation of $67 million for the OPTN Modernization Initiative for fiscal year 2025, a $13 million increase from the prior year, signals a commitment to integrating advanced technologies, directly benefiting manufacturers of organ care products.

This dominant market position in the organ care products market is cemented by a highly favorable regulatory and commercialization landscape. In a landmark achievement, Paragonix received FDA 510(k) clearance for its KidneyVault system in October 2024, making it the only company with U.S. regulatory clearances for all five solid transplant organs. The rapid adoption of such technologies is evident, with the KidneyVault system achieving its one-hundredth case by April 2025. This demonstrates a market that not only has high volume but is also quick to embrace innovation that improves outcomes. For manufacturers, North America represents the largest, most mature, and most financially accessible market, where cutting-edge organ care products can achieve rapid clinical adoption and commercial success, setting global standards.

Europe: A Region of Collaborative Growth and Regulatory Advancement

Europe holds a strong second position in the organ care products market, distinguished by its highly organized, collaborative transplant networks and a stringent regulatory framework that champions advanced technology. The eight-country Eurotransplant network is a prime example, having allocated 7,150 organs from 2,181 deceased donors in 2024. While these numbers are significant, the year ended with 13,570 patients still active on the waiting list, highlighting a persistent and urgent need for solutions that maximize organ utilization. The United Kingdom's 2023-2024 data further illustrates this, with 1,510 deceased donors (comprising 738 DCD and 772 DBD donors) supporting the system, while 7,484 patients remained on the active waiting list as of March 2024, plus another 3,795 temporarily suspended. This significant gap between supply and demand is a powerful driver for the adoption of advanced preservation products.

The European market is particularly receptive to technologies that enable more complex procedures and ensure quality. The performance of 65 DCD heart transplants in the UK during 2023/2024 showcases the region's clinical expertise and reliance on superior organ care technology. For manufacturers, achieving regulatory approval in Europe is a critical milestone that validates product quality and opens access to a sophisticated customer base. Paragonix’s EU MDR approval for five of its devices in March 2025, and its subsequent utilization at over 40 EU transplant centers, demonstrates the region's importance. Success in Europe signals a product's alignment with high clinical standards, making it a vital, albeit complex, market for any major player in the organ care products industry.

Asia-Pacific: A Region of Rapid Growth and Emerging Potential

The Asia-Pacific region is the most dynamic and rapidly emerging force in the global organ care products market, defined by exponential growth in donation and transplant activities. China is at the forefront of this expansion, recording 6,744 organ donations that led to an incredible 24,684 transplant surgeries in 2024. The foundation for future growth is immense, with over 7.05 million people registered as organ donors by early 2025. Other nations are also building momentum; Japan saw a record 139 brain-dead organ donors in fiscal year 2024, supplying organs for 119 liver and 116 heart transplants. India is also scaling up dramatically, with deceased donors increasing to 1,128 in 2024, supporting 26,738 kidney and 9,720 liver transplants. This surge in procedural volume across the region is creating a vast, untapped market for organ care products.

This growth is coupled with a clear and urgent need, as evidenced by over 16,000 patients on Japan’s waiting list as of May 2024. National programs are also strengthening; Australia recorded 527 deceased donors in 2024, enabling 1,328 transplants, and saw 173,414 new registrations on its donor register. While the Asia-Pacific market is still maturing compared to North America and Europe, its sheer scale and rapid year-over-year growth in transplant activity represent the most significant long-term opportunity for the organ care products industry. Companies that can navigate the diverse regulatory and logistical landscapes of this region will be well-positioned to capitalize on the next wave of global market expansion.

Top 10 Expansions and Investments Defining Future of Organ Care Products Market 

• In April 2025, Paragonix Technologies announced that its KidneyVault™ system, which received FDA clearance in late 2024, had been successfully used in its one-hundredth transplant case, marking a rapid expansion of its commercial footprint in the renal transport market.
• In March 2025, Paragonix Technologies secured crucial European Union Medical Device Regulation (MDR) certification for five of its advanced organ preservation devices, significantly expanding its market access and sales potential across all EU member states.
• In February 2025, Enduring Hearts announced a new $1.2 million funding initiative to support research projects focused on improving longevity and outcomes for pediatric heart transplant recipients, directly fueling innovation in specialized organ care.
• In January 2025, the International Society for Heart & Lung Transplantation (ISHLT) announced the recipients of its research grant of up to $75,000, funding new investigations into DCD heart transplantation, a key growth area for advanced perfusion technology.
• In December 2024, Bridge to Life Ltd. completed the first human clinical use of its LifeCradle® Heart Perfusion System, a major development in its portfolio expansion following years of focused investment in R&D for cardiac preservation.
• In October 2024, the U.S. Senate Appropriations Committee approved a significant funding increase for the OPTN Modernization Initiative, allocating $67 million for fiscal year 2025 to overhaul the nation's transplant system, boosting investment in advanced IT and logistics.
• In June 2024, Paragonix Technologies announced the launch of its PancreasPak, the first FDA-cleared device for pancreas preservation, representing a major product portfolio expansion into a new organ segment of the organ care products market.
• In April 2024, Paragonix announced the full commercial launch of its BAROguard Donor Lung Preservation System in the United States, a strategic expansion following a successful limited market release at top transplant centers.
• In March 2024, the U.S. government allocated an additional $23 million to the HRSA OPTN Modernization Initiative as part of the FY24 funding package, bringing the total investment for that year to $52 million.
• In February 2024, the Mid-America Transplant Foundation opened applications for its Clinical Innovation Fund, offering multi-year awards of up to $150,000 annually to spur research and development in organ recovery and transplantation.

Top Companies in the Organ Care Products Market

• Bridge to Life Ltd.
• TransMedics Inc.
• Organ Recovery system
• XVIVO
• Preservation Solution Inc.
• Paragonix technologies and IGL
• OrganOx Limited
• Other Prominent Players

Market Segmentation Overview

By Organ Type

• Kidney
• Liver
• Heart
• Lungs
• Others

By Product Type

• Trolly
• Portable

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Hungary
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • UAE
  • Saudi Arabia
  • Bahrain
  • Kuwait
  • Qatar
  • Rest of Middle East
• Africa
  • Oman
  • Egypt
  • Nigeria
  • South Africa
  • Rest of Africa
• South America
  • Argentina
  • Brazil
  • Rest of South America